Drug Profile

Landogrozumab - Eli Lilly and Company

Alternative Names: LY-2495655

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eli Lilly and Company
Class Monoclonal antibodies
Mechanism of Action Myostatin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Cachexia; Cancer; Muscular atrophy; Pancreatic cancer

Most Recent Events

08 Sep 2021 Discontinued - Phase-I for Cancer in USA (IV)
08 Sep 2021 Discontinued - Phase-I for Muscular atrophy (In volunteers) in USA (IV)
08 Sep 2021 Discontinued - Phase-II for Cachexia in USA, Israel, United Kingdom, Canada, Norway, Belgium, Belgium (IV) before September 2021 (Eli Lilly and Company pipeline, September 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com